US/UK/Canada

Share

Contacts

  • ODI Pharma AB
    Östermalmstorg 1, 11442 Stockholm
    +41765733788
    http://Odipharma.com
    • Pick a time period -
    Tags ( Active)

    ODI Pharma terminates the agreement with liquidity provider

    ODI Pharma AB ("ODI Pharma") hereby informs the termination of the agreement regarding the liquidity provider with Pareto Securities AB. The last day for the service of liquidity support by Pareto is March 14, 2025.The purpose of the liquidity provider has been to increase the liquidity of stock trading and reduce the volatility of the Company’s stock to facilitate trading. The agreement with Parteo has now been terminated and will expire on March 14, 2025. For more information on ODI Pharma, please contact: Volker Wiederrich, Chairman, ODI Pharma AB E-mail: info@odipharma.com

    Announcement from the Annual General Meeting in ODI Pharma AB (publ)

    Today, the 30[th] of December 2024, ODI Pharma AB (publ) held its Annual General Meeting (“AGM”). A summary of the resolutions follows below. The resolutions were made with the required majority. For more detailed information on the content of the resolutions, please refer to the notice of the Annual General Meeting.Adoption of the income statement and balance sheet The AGM resolved to adopt the profit and loss account and balance sheet presented, and the consolidated income statement and consolidated balance sheet. Allocation of the company’s profit or loss The AGM resolved to

    ODI Pharma AB announces last day of trading in BTA

    ODI Pharma AB’s ("ODI" or the "Company") preferential issue of shares, with a subscription period ending on December 10, 2024, has now been registered at the Swedish Companies Registration Office. The Company hereby announces that the last day of trading in BTA (paid subscribed share) is December 27, 2024, and the stop day is January 2, 2025.In November 2024, ODI carried out a rights issue which provided the Company with approximately SEK 2.2 million before transaction costs. The rights issue has now been registered at the Swedish Companies Registration Office and the last day of trading in

    ODI Pharma AB publishes outcome of rights issue

    The subscription period in ODI Pharma AB’s ("ODI" or the "Company") issue of shares with preferential right (the “Rights Issue”) ended on December 10, 2024. The Rights Issue was subscribed to a total of approximately 54.8 percent, including pre-subscription commitments. ODI will thus be provided proceeds of approximately SEK 2.2 million before deduction of transaction related costs.Subscription, allocation and payment The Rights Issue was subscribed to approximately SEK 2.2 million including pre-subscription commitments of approximately SEK 2.0 million, which corresponds to a

    ODI Pharma achieved market share targets in 2024 and increases its targets for 2025. Positioned for growth as Poland's medical cannabis market expands.

    ODI Pharma AB ("ODI" or the "Company") provides an update on Poland’s expanding medical cannabis market, which remains an important focus of the Company’s strategy. Recent regulatory changes in Poland highlight ODI’s established position in one of Europe’s most promising markets for medical cannabis.With ODI Pharma’s sales during the current calendar year, ODI Pharma reached it’s previously stipulated goal of achieving a substantial market share of more than 10%, resulting in a positive operational result for the shareholders of ODI for the financial year 2023/2024. ODI Pharma has

    Notice of Extraordinary General Meeting in ODI Pharma AB (publ)

    The shareholders of ODI Pharma AB (publ), 559223-1392, are hereby invited to an Extraordinary General Meeting to be held on Tuesday 19 November 2024 at 14.30 at the company's premises at Östermalmstorg 1, 114 42 in Stockholm.Eligibility and registration Shareholders who wish to participate in the General Meeting shall · be entered in the share register maintained by Euroclear Sweden AB on 11 November 2024, and · notify the company no later than on 13 November 2024 by e-mail to info@odipharma.com. The notification shall state full name, personal or corporate identity number,

    Proposal for change in the Board of Directors of ODI Pharma AB

    Malcolm Allan is proposed to be elected as a new member of the Board of Directors of ODI Pharma AB at the Extraordinary General Meeting on November 19, 2024.Malcolm Allan has extensive experience in senior positions within global companies and political campaigns. For the past three years, he has been serving as Vice President at Tilray Brands Inc. Prior to that, he was the Global COO for Havas Media and Managing Director for Prudential in London, UK. He holds a Bachelor of Arts with honors in Political Science and Economics from McGill University.  For more information about the

    ODI Pharma AB decides on a preferential issue of shares and to bring forward publication of the Q1-report

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM SWEDISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE. The Board of Directors of ODI Pharma AB ("ODI" or the "Company") has today, on October 30, 2024, resolved to carry out an issue of shares (the "

    ODI Pharma AB announces strategic market entry with initial shipment to Switzerland

    ODI Pharma AB (“ODI” or the “Company”) is pleased to announce the first delivery of cannabis products to the leading medical cannabis provider in Switzerland. The delivery marks a symbolic milestone in ODI's market expansion efforts as it is the first delivery to the Swiss market. The delivery, which is facilitated through ODI’s Swiss subsidiary, is less significant in terms of economic value but more important from a strategic point of view.Exploration of Other European Markets ODI Pharma is consolidating its position in the Eastern European medical cannabis market and is exploring

    ODI Pharma AB: Publication of interim report Q3 2023/2024

    ODI Pharma AB (“ODI” or the “Company”) hereby publishes its interim report for the period July 2023 - March 2024. The report is available as an attached document to this press release and on the Company’s website (www.odipharma.com). Below is a summary of the report.Third quarter (2024-01-01 – 2024-03-31)The Group's net sales amounted to SEK 13,856,539 (10,801).The Group's profit after financial items amounted to SEK 1,389,713 (-942,440).Result per share amounted to SEK 0,09 (-0.06).*  Nine months (2023-07-01 – 2024-03-31)The Group’s net sales amounted to SEK 14,777,194 (112,

    Preliminary results for ODI Pharma indicate significant revenue increase in Q3 2023/2024

    ODI Pharma AB (“ODI” or the “Company”) announces today that the preliminary financial results for the third quarter of fiscal year 2023/2024 are expected to surpass current market expectations. Initial figures for this period indicate that revenues will exceed SEK 13.5 million. This growth mainly comes from an increase in orders following our strategic partnership in Eastern Europe."These extraordinary results mark a turning point in ODI Pharma’s operations and demonstrate the potential of our business model. The substantial increase in orders, following our collaboration with Synoptis

    ODI Pharma AB: Updated market and business overview

    ODI Pharma AB (“ODI” or the “Company”) hereby present an updated overview of its market position and the latest trends observed in the cannabis industry, particularly in Europe.Progress in the cooperation with Synoptis Pharma Since August 2023, ODI Pharma's exclusive cooperation with Synoptis Pharma (“Synoptis”), integral to the NEUCA group (“NEUCA”), has made notable progress. This alliance, spanning Poland and 23 other countries in Eastern Europe, has effectively executed several product shipments in recent months. These initial orders highlight the increasing demand and showcase ODI's

    ODI Pharma AB appoints Pareto Securities AB as liquidity provider

    ODI Pharma AB (“ODI Pharma” or the “Company”) has today appointed Pareto Securities as the liquidity guarantor for the Company's shares, which are listed for trading on the Spotlight Stock Market. The purpose of the liquidity guarantee is to improve the liquidity of the stock and to reduce the difference between the buying and selling price. The assignment will begin on 19 January 2024.A liquidity provider is an entity that undertakes to promote the trading of a share by ensuring that there are always buy and sell orders in the order book. Pareto Securities, in its role as liquidity

    Announcement from the Annual General Meeting in ODI Pharma AB (publ)

    This is an unofficial translation of a notice to the Annual General Meeting in ODI Pharma AB (publ), originally drafted in Swedish. In case of any discrepancies between the Swedish original and this translation, the Swedish version shall prevail. Today, the 15[th] of December 2023, ODI Pharma AB (publ) held its Annual General Meeting (“AGM”). A summary of the resolutions follows below. The resolutions were made with the required majority.Adoption of the income statement and balance sheet The AGM resolved to adopt the profit and loss account and balance sheet presented, and the

    ODI Pharma AB announces sale of the skincare brand kandol. for 3.2 msek

    ODI Pharma AB (“ODI” or the “Company”) announces today the sale of the skincare brand kandol. to Niclas Kappelin. The transaction, valued at 3.2 million SEK, includes the transfer of all inventories, production materials, trademarks, and copyrights associated with kandol. In connection with the transaction, CEO Derek Simmross and Chairman of the Board Volker Wiederrich will transfer 2,300,000 and 200,000 shares, off market, respectively to the buyer as part of the transaction.ODI announces that the Company has sold the skincare brand kandol. to the main shareholder Niclas Kappelin for 3.2

    Correction: ODI Pharma AB publishes the annual report for the fiscal year 2022/2023

    The correction refers to the completion of the auditor's remark and ODI Pharma's comment which is now included in the press release. The attached annual report, which includes the auditor's report, is unchanged. The Board of Directors and the Chief Executive Officer of ODI Pharma AB (“ODI Pharma”) hereby publishes the annual report for the fiscal year 2022/2023. The annual report, along with the accompanying auditor’s report, is available as an attached file and on the websites of ODI Pharma (www.odipharma.com) and Spotlight Stock Market (www.spotlightstockmarket.com). A Swedish

    ODI Pharma AB publishes the annual report for the fiscal year 2022/2023

    The Board of Directors and the Chief Executive Officer of ODI Pharma AB (“ODI Pharma”) hereby publishes the annual report for the fiscal year 2022/2023. The annual report, along with the accompanying auditor’s report, is available as an attached file and on the websites of ODI Pharma (www.odipharma.com) and Spotlight Stock Market (www.spotlightstockmarket.com). A Swedish translation of the annual report is also available on www.odipharma.com.For more information on ODI Pharma, please contact: Derek Simmross, CEO, ODI Pharma AB                                                E-mail:

    ODI Pharma AB: Publication of interim report report Q1 2023/2024

    ODI Pharma AB (“ODI” or the “Company”) hereby publishes its interim report for the period July 2023 – September 2023. The report is available as an attached document to this press release and on the Company’s website (www.odipharma.com). Below is a summary of the report.First quarter (2023-07-01 – 2023-09-30) The Group's net sales amounted to SEK 528 206 (28 006). The Group's loss after financial items amounted to SEK -1 442 544 (-1 598 205). Result per share amounted to SEK -0.09 (-0.11).* The solidity as of 2023-09-30 was 15% (90%).** * The Company’s result per share: The

    ODI Pharma AB postpones publication of interim report and annual report until November 24, 2023

    ODI Pharma AB (“ODI” or the “Company”) stated in its year-end report that the interim report for the first quarter of 2023/2024 and the annual report for the fiscal year 2022/2023 would be published on November 23, 2023. Instead, the interim report and the annual report will be published on November 24, 2023, three weeks before the Annual General Meeting on December 15, 2023.For more information, please contact: Derek Simmross, CEO, ODI Pharma AB E-mail: info@odipharma.com

    Notice to Annual General Meeting in ODI Pharma AB (publ)

    The shareholders of ODI Pharma AB (publ), 559223–1392, are hereby invited to attend the Annual General Meeting on Friday, 15th of December 2023, at 10.30 in the office of the company at Östermalmstorg 1, 114 42 Stockholm.Right to participate and registrationShareholders who wish to attend the Annual General Meeting shall · be included in the Euroclear Sweden AB share no later than Thursday the 7[th ]of December 2023, and · sign up to the company no later than Monday the 11[th] of December 2023, by e-mail to info@odipharma.com. The notification should state the full name, personal

    ODI Pharma AB: Publication of year-end report for the fiscal year 2022/2023

    ODI Pharma AB (“ODI” or the “Company”) hereby publishes its year-end report for the period July 2022 – June 2023. The report is available as an attached document to this press release and on the Company’s website (www.odipharma.com). Below is a summary of the report.Fourth quarter (2023-04-01 – 2023-06-30) The Group's net sales amounted to SEK 38 418 (14 233) The Group's loss after financial items amounted to SEK -1 896 506 (-2 378 022) Result per share amounted to SEK -0,12 (-0,16)* Fiscal year (2022-07-01 – 2023-06-30) The Group's net sales amounted to SEK 139 457 (544 151)

    ODI Pharma AB enters into exclusive collaboration with Synoptis Pharma Sp. z o.o.

    ODI Pharma AB (“ODI” or “the Company”) hereby announces that the Company has entered through its Polish subsidiary into a collaboration agreement (“Agreement”) with Synoptis Pharma Sp. Z o.o. (“Synoptis”) under which ODI becomes the exclusive supply partner for medicinal cannabis flos products to Synoptis for a period of 5 plus additional optional 3.5 years covering all Eastern and South Eastern European markets, including Poland, Czech Republic, Ukraine, Croatia etc.Milestone for ODI ODI has secured a prime pharmaceutical company in the Eastern European markets as its collaboration

    ODI Pharma AB receives loan financing of EUR 350,000

    ODI Pharma AB (“ODI” or “the Company”) hereby announces that the Company has secured loan financing of EUR 350,000 from an external international party in order to create flexibility in the operations.Loan financing terms and purpose in summary ODI has, as communicated in January 2023, received approval of the Company’s Marketing Authorization Holder (MAH) application from the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in Poland to distribute and sell its products on the Polish market. The Company thus has the right to distribute and sell its

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe